← All trials
NCT05058404
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Jul 31, 2028
- Completion date
- Jul 31, 2030
- First posted
- Sep 27, 2021
- Last posted
- Sep 27, 2021
- Enrollment
- 602
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fondazione Italiana Diabete OnlusLead sponsor
- University of Modena and Reggio EmiliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.